Literature DB >> 28764616

Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes.

S Piantoni1,2, F Regola1, A Zanola1, L Andreoli1, F Dall'Ara1, A Tincani1, P Airo'3.   

Abstract

Background and objectives T-cell activation may be one of the pathogenic mechanisms of systemic lupus erythematosus (SLE). After repeated antigenic stimulation, T-cells undergo different modifications, leading to the differentiation into effector memory T-cells (CCR7-CD45RA-) and terminally differentiated effector memory (TDEM) T-cells (CCR7-CD45RA+). Similarly, down-modulation of CD28 may lead to the expansion of the CD28- T-cells, a subpopulation with peculiar effector activities. The aim of this study was the characterization of T-cell phenotype in a cohort of patients with SLE according to disease activity and damage index. Materials and methods Phenotypic analysis of peripheral blood T lymphocytes of 51 SLE patients and 21 healthy controls was done by flow-cytometry. SLE disease activity was evaluated by SLE Disease Activity Index-2000 (SLEDAI-2K) and damage by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI). The variations between different groups were evaluated by Mann-Whitney test. Bonferroni correction was applied to adjust for multiple comparisons ( padj). Spearman rank test was used to evaluate the correlations between quantitative variables. Results CD4+ lymphopenia was found among SLE patients. Patients showed a trend for a higher percentage of TDEM among the CD4+ T-cell subpopulation in comparison with healthy controls ( p = .04). SLE patients were divided into two groups according to disease activity: patients with SLEDAI-2K ≥ 6 ( n = 13) had a higher percentage of circulating CD4+ T-cells with CD28- phenotype ( padj = .005) as well as those with an effector memory ( padj = .004) and TDEM ( padj = .002) phenotype and a trend of decrease of regulatory T-cells (TREGs) ( p = .02), in comparison with patients with low disease activity ( n = 38). Patients with damage (SDI ≥ 1) tended to show an expansion of TDEM among CD4+ T-cells as compared with patients with no damage ( p = .01). In SLE patients an inverse correlation was found between the percentages of TREGs and those of TDEM ( p < .01) or CD4 + CD28- ( p < .01) T-cells. Conclusions CD4+ T-cell subpopulations displaying phenotype characteristics of effector lymphocytes are proportionally expanded in patients with active SLE and a higher damage index. These findings may suggest a role of effector T-cells in the pathogenesis of the disease and in the mechanisms of damage in SLE.

Entities:  

Keywords:  Systemic lupus erythematosus; T-cells; damage; disease activity

Mesh:

Year:  2017        PMID: 28764616     DOI: 10.1177/0961203317722848

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients.

Authors:  Matthias Schaier; Claudius Gottschalk; Lorenz Uhlmann; Claudius Speer; Florian Kälble; Volker Eckstein; Carsten Müller-Tidow; Stefan Meuer; Karsten Mahnke; Hanns-Martin Lorenz; Martin Zeier; Andrea Steinborn
Journal:  Arthritis Res Ther       Date:  2018-12-18       Impact factor: 5.156

Review 2.  CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection.

Authors:  Aalia Bano; Alejandra Pera; Ahmad Almoukayed; Thomas H S Clarke; Sukaina Kirmani; Kevin A Davies; Florian Kern
Journal:  F1000Res       Date:  2019-03-25

3.  Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.

Authors:  Cindy Orvain; Anne Cauvet; Alexis Prudent; Christophe Guignabert; Raphaël Thuillet; Mina Ottaviani; Ly Tu; Fanny Duhalde; Carole Nicco; Frédéric Batteux; Jérôme Avouac; NingXin Wang; Michelle A Seaberg; Stacey R Dillon; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2022-01-05       Impact factor: 5.156

4.  Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients.

Authors:  Huijing Wang; Lan Lan; Jianghua Chen; Liang Xiao; Fei Han
Journal:  Lupus Sci Med       Date:  2022-08

5.  Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.

Authors:  Silvia Piantoni; Francesca Regola; Stefania Masneri; Michele Merletti; Torsten Lowin; Paolo Airò; Angela Tincani; Franco Franceschini; Laura Andreoli; Georg Pongratz
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

6.  Altered Cell Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus Erythematosus.

Authors:  Enikő Szabó; Ákos Hornung; Éva Monostori; Márta Bocskai; Ágnes Czibula; László Kovács
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

7.  The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus.

Authors:  Alessandra Bortoluzzi; Cecilia Beatrice Chighizola; Micaela Fredi; Elena Raschi; Caterina Bodio; Daniela Privitera; Arianna Gonelli; Ettore Silvagni; Marcello Govoni; Ilaria Cavazzana; Paolo Airò; Pier Luigi Meroni; Angela Tincani; Franco Franceschini; Silvia Piantoni; Fabio Casciano
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

8.  First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.

Authors:  Jing Yang; Jason D Lickliter; Jan L Hillson; Gary D Means; Russell J Sanderson; Kay Carley; Almudena Tercero; Kristi L Manjarrez; Jennifer R Wiley; Stanford L Peng
Journal:  Clin Transl Sci       Date:  2021-03-02       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.